NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
OMCL
Omnicell, Inc.
OMCL has the edge over NVO overall, supported by stronger valuation and stronger fundamentals.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
OMCL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
OMCL's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
OMCL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $34.95 | — |
| Current | 36x | $34.95 | — |
| Cheap | 52x | $49.71 | +42% |
| Fair | 79x | $75.94 | +117% |
| Expensive | 153x | $147 | +320% |
Historical ranges are pointers, not guarantees.
OMCL has the edge over NVO in the historical PE scenario, which offers more potential upside but is not a forecast.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
OMCL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect OMCL's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over OMCL on earnings, with more consistent year-over-year improvement.
OMCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.92 | +100% |
| Q3 2026 | $0.96 | +123% |
| Q2 2026 | $0.84 | +68% |
| Q1 2026 | $0.44 | -4.3% |
| Q4 2025 | $0.04 | -85% |
| Q3 2025 | $0.43 | +$0.82 |
| Q2 2025 | $0.50 | +$0.96 |
| Q1 2025 | $0.46 | +$0.92 |
| Q4 2024 | $0.27 | +$0.72 |
OMCL's earnings per share have fallen from their peak: $0.96 over the past year, against $1.72 in late 2021.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over OMCL on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over OMCL on profitability, with a higher operating margin.
OMCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $307.9M | -0.9% |
| Q2 2026 | $312.2M | +7.4% |
| Q1 2026 | $309.9M | +15% |
| Q4 2025 | $314M | +2.3% |
| Q3 2025 | $310.6M | +10% |
| Q2 2025 | $290.6M | +5% |
| Q1 2025 | $269.7M | +9.6% |
| Q4 2024 | $306.9M | +19% |
OMCL's revenue is growing: $308M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.8% | +2.2 points |
| Q2 2026 | 10% | +7.6 points |
| Q1 2026 | 5.4% | +9.8 points |
| Q4 2025 | 0.1% | -3.9 points |
| Q3 2025 | 2.6% | +0.3 points |
| Q2 2025 | 2.8% | +1.6 points |
| Q1 2025 | -4.3% | +4.6 points |
| Q4 2024 | 4% | +13 points |
OMCL's operating margin was 4.8% last quarter, up 2.2 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
OMCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.7M | +17% |
| Q2 2026 | $59.4M | +92% |
| Q1 2026 | $42.1M | +185% |
| Q4 2025 | $22.6M | -52% |
| Q3 2025 | $18.5M | +33% |
| Q2 2025 | $31M | -37% |
| Q1 2025 | $14.8M | -64% |
| Q4 2024 | $47.2M | +61% |
OMCL still generates free cash flow, though less than at its 2020 peak: $146M over the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over OMCL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
OMCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +164K shares |
| 1 year | +1.2% | +566K shares |
| 3 years | +1.9% | +871K shares |
| 5 years | -3.9% | -1.9M shares |
| Available history | +8.2% | +3.5M shares |
OMCL has 46M diluted shares, up 1.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $61.9M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
OMCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.0x | Net Cash |
| Q2 2026 | -0.9x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.6x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | -0.3x | Net Cash |
OMCL has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
OMCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.4 | Neutral |
| Stochastic | 46.9 | Neutral |
OMCL's weekly RSI is 45 (neutral) and its Stochastic is 47 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over OMCL on valuation relative to its sector.
OMCL PE vs Healthcare Sector
| Metric | OMCL | Sector median | Relative |
|---|---|---|---|
| PE | 36x | 26x | 41% above |
| PE % | 0 | 29 | 29 pts below |
OMCL is trading at 36x earnings, a 41% premium to the Healthcare sector's median of 26x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over OMCL on trend strength, trading above more of its moving averages.
OMCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $35.7 | 2% below |
| 20 week MA | $36.9 | 5.2% below |
| 50 week MA | $39.6 | 12% below |
| 100 week MA | $36.7 | 4.7% below |
| 200 week MA | $40.9 | 15% below |
OMCL is in a downtrend: it's below all five of its weekly moving averages, and 15% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over OMCL on returns for 2026, with the stronger performance.
OMCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $82.5 | $118.2 | +43% |
| 2021 | $118.2 | $175.7 | +49% |
| 2022 | $175.7 | $48.4 | -72% |
| 2023 | $48.4 | $37.6 | -22% |
| 2024 | $37.6 | $44.1 | +17% |
| 2025 | $44.1 | $46.4 | +5.3% |
| 2026 YTD | $46.4 | $35.0 | -25% |
OMCL has finished higher in four of the last six years. It's down 25% so far in 2026.